Ubs Group Ag Summit Therapeutics Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,278,783 shares of SMMT stock, worth $23.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,278,783

Previous 2,093,958 38.93%

Holding current value

$23.3 Million

Previous $44.6 Million 40.51%

% of portfolio

0.0%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$17.61 - $30.02 $14.4 Million - $24.5 Million	-815,175 Reduced 38.93%	1,278,783 $26.5 Million
Q2 2025 Aug 14, 2025	BUY	$16.64 - $36.7 $13.8 Million - $30.5 Million	829,735 Added 65.63%	2,093,958 $44.6 Million
Q1 2025 May 13, 2025	BUY	$16.65 - $23.76 $1.3 Million - $1.85 Million	77,873 Added 6.56%	1,264,223 $24.4 Million
Q4 2024 Feb 14, 2025	BUY	$17.52 - $23.46 $18.7 Million - $25 Million	1,066,531 Added 890.12%	1,186,350 $21.2 Million
Q3 2024 Nov 14, 2024	SELL	$6.89 - $31.93 $331,050 - $1.53 Million	-48,048 Reduced 28.62%	119,819 $2.62 Million
Q2 2024 Aug 13, 2024	SELL	$2.39 - $10.92 $738,689 - $3.38 Million	-309,075 Reduced 64.8%	167,867 $1.31 Million
Q1 2024 May 13, 2024	BUY	$2.55 - $5.07 $830,468 - $1.65 Million	325,674 Added 215.3%	476,942 $1.97 Million
Q4 2023 Feb 09, 2024	BUY	$1.67 - $2.83 $89,314 - $151,354	53,482 Added 54.69%	151,268 $394,000
Q3 2023 Nov 09, 2023	BUY	$1.54 - $2.42 $69,994 - $109,991	45,451 Added 86.85%	97,786 $182,000
Q2 2023 Aug 11, 2023	SELL	$1.32 - $2.81 $145,334 - $309,386	-110,102 Reduced 67.78%	52,335 $131,000
Q1 2023 May 12, 2023	BUY	$1.38 - $5.41 $220,812 - $865,648	160,009 Added 6590.16%	162,437 $284,000
Q4 2022 Feb 08, 2023	SELL	$0.68 - $5.31 $31,835 - $248,598	-46,817 Reduced 95.07%	2,428 $10,000
Q3 2022 Nov 10, 2022	SELL	$0.89 - $1.63 $12,540 - $22,968	-14,091 Reduced 22.25%	49,245 $58,000
Q2 2022 Aug 10, 2022	SELL	$0.92 - $2.38 $17,349 - $44,882	-18,858 Reduced 22.94%	63,336 $63,000
Q1 2022 May 16, 2022	SELL	$2.0 - $3.45 $68,218 - $117,676	-34,109 Reduced 29.33%	82,194 $201,000
Q4 2021 Feb 14, 2022	SELL	$2.45 - $5.64 $19,693 - $45,334	-8,038 Reduced 6.46%	116,303 $313,000
Q3 2021 Nov 15, 2021	SELL	$4.83 - $8.27 $2,187 - $3,746	-453 Reduced 0.36%	124,341 $623,000
Q2 2021 Aug 13, 2021	SELL	$5.15 - $8.46 $6,071 - $9,974	-1,179 Reduced 0.94%	124,794 $931,000
Q1 2021 May 12, 2021	SELL	$5.17 - $11.19 $63,663 - $137,793	-12,314 Reduced 8.9%	125,973 $739,000
Q4 2020 Feb 11, 2021	SELL	$3.25 - $6.0 $8,687 - $16,038	-2,673 Reduced 1.9%	138,287 $650,000
Q3 2020 Nov 12, 2020	BUY	$3.08 - $3.8 $434,156 - $535,648	140,960 New	140,960 $485,000

Others Institutions Holding SMMT

# of Institutions

269

Shares Held

95.1M

Call Options Held

4.72M

Put Options Held

4.03M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.67B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account